The Nobel Committee awarded the 2026 chemistry prize on Wednesday to Henri B. Kagan, 95, of the Université Paris-Sud in France, and Kenso Soai, 76, of Tokyo University of Science in Japan, for what the committee called the “discovery of non-linear effects and autocatalysis in asymmetric organic synthesis.” The winners will receive 12 million Swedish kronor, roughly $1.2 million.
The problem they solved is central to pharmacology. Many molecules exist as mirror images, a phenomenon known as chirality, and a living organism can typically use only one version. Before their work, chemists developing new drugs had essentially no way to produce one mirror image without its twin, so most drugs were sold as racemates containing equal mixtures of both. The mirror molecule sometimes does something completely different from what was intended, and sometimes causes serious side effects.
Kagan found in 1986 how to manipulate reactions to favor one mirror image. Seventeen years later, Soai developed an experiment that created only one of the two variants from non-chiral starting materials for the first time, in what one committee member called the “coolest experiment in organic chemistry.” More than half of clinically employed drugs are chiral, and from a pharmaceutical point of view the work opened the door to chiral drugs containing only the necessary version of the molecule, achieving greater precision with lower side effects. The prize is a fitting bookend to a week of life-sciences news that keeps returning to the same question: how much precision the technology actually delivers against what it promises.